Evinco Therapeutics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia, developing first-in-class immune-based therapies for neurological disorders.
The Company is advancing a novel platform built on Natural Killer cell–derived extracellular vesicles (NK-EVs), with an initial focus on Alzheimer’s disease – one of the largest and fastest-growing global markets in medicine. NK-EVs are biologically active nano-vesicles capable of modulating neuroinflammation and targeting key pathological drivers of disease progression.
Evinco’s differentiated approach includes intranasal delivery, a non-invasive strategy designed to enable direct brain access while avoiding the limitations of systemic biologics. This positions the platform for improved safety, scalability, and patient accessibility.
Supported by compelling preclinical data and backed by experienced leadership, including world-renowned stem cell pioneer, Prof. Alan Trounson AO, Evinco Therapeutics is positioned to deliver a transformative therapy with global reach and significant commercial upside.
Evinco Therapeutics is a subsidiary of Cartherics Pty Ltd.